Noun
bevacizumab (uncountable)
(pharmacology) An anticancer drug that is a genetically engineered monoclonal antibody administered intravenously to slow or inhibit tumor growth especially in some metastatic forms of cancer (such as colorectal cancer). It acts by binding to and inhibiting the activity of vascular endothelial growth factor, a protein that promotes the growth of new blood vessels which supply a spreading tumor. It is marketed under the trademark Avastin.
A: The study allowed patients who had received first-line standard combination chemotherapy with bevacizumab to go on to receive second-line chemotherapy plus cetuximab with or without the novel anti-VEGF anti-body ramucirumab. Source: Internet
Roche announced today that the European Commission confirmed that Avastin (bevacizumab) in combination with paclitaxel will remain a treatment option for women with metastatic breast cancer in Europe. Source: Internet